Skip to main content

Characterization of Most Frequent Diagnoses, Procedures, Medications and Labs Associated with Use of Finerenone in TriNetX: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
finerenone
Description

In this report we aimed to detail the most frequent diagnoses, procedures, medications and labs associated with use of finerenone, a new molecular entity (NME) approved by the FDA in 2021 using the TriNetX Live™ platform.

The study period includes data from December 18, 2020 to February 29, 2024. We ran this analysis on April 17 and 18, 2024. This query contains data from 60 health care organizations (HCOs), provided through the TriNetX Live™ platform in their USA Network with Minimal Shift.

Deliverables (1)
Sentinel Modular Program Report: Characterization of Most Frequent Diagnoses, Procedures, Medications and Labs Associated with Use of Finerenone in TriNetX: A Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
December 18, 2020 - February 29, 2024
Analysis Type
TriNetX Analysis
Population / Cohort
All individuals
Data Sources
TriNetX Live™ USA Network
Related Links
Sentinel Drug Study: New Molecular Entities (NMEs) & Utilization Characterization